Sialylation of Thomsen-Friedenreich antigen is a noninvasive blood-based biomarker for GNE myopathy

Biomarkers in Medicine

Volumn 8, Issue 5, 2014, Pages 641-652

  Leoyklang, Petcharat ^a   Malicdan, May Christine ^a   Yardeni, Tal ^a,b   Celeste, Frank ^c   Ciccone, Carla ^a   Li, Xueli ^d,e   Jiang, Rong ^d   Gahl, William A ^a   Carrillo Carrasco, Nuria ^c   He, Miao ^d,e   Huizing, Marjan ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b TEL AVIV UNIVERSITY   (Israel)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

core 1 O linked glycan; glycosylation; hereditary inclusion body myopathy; L MS MS; lectin; N acetylmannosamine (ManNAc); sialic acid; ST antigen

Indexed keywords

BIOLOGICAL MARKER; GLYCAN; IMMUNOGLOBULIN; LECTIN; NERVE CELL ADHESION MOLECULE; PLASMA PROTEIN; THOMSEN FRIEDENREICH ANTIGEN; UNCLASSIFIED DRUG; MULTIENZYME COMPLEX; N ACETYLNEURAMINIC ACID; POLYSACCHARIDE; THOMSEN-FRIEDENREICH ANTIGEN; TUMOR ANTIGEN; UDP-N-ACETYLGLUCOSAMINE 2-EPIMERASE - N-ACETYLMANNOSAMINE KINASE;

ARTICLE; BICEPS BRACHII MUSCLE; BLOOD ANALYSIS; CONTROLLED STUDY; GASTROCNEMIUS MUSCLE; GENE MUTATION; GNE GENE; GNE MYOPATHY; HISTOCHEMISTRY; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; INCLUSION BODY MYOSITIS; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; MATRIX ASSISTED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; MUSCLE BIOPSY; NON INVASIVE MEASUREMENT; REPRODUCIBILITY; SIALYLATION; BLOOD; ENZYMOLOGY; METABOLISM; MUSCLE DISEASE;

ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOMARKERS; HUMANS; LECTINS; MULTIENZYME COMPLEXES; MUSCULAR DISEASES; N-ACETYLNEURAMINIC ACID; NEURAL CELL ADHESION MOLECULES; POLYSACCHARIDES;

EID: 84906237895     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm.14.2     Document Type: Article

References (54)

1. Yunis EJ, Samaha FJ. Inclusion body myositis. Lab. Invest. 25(3), 240-248 (1971).
2. Griggs RC, Askanas V, DiMauro S et al. Inclusion body myositis and myopathies. Ann. Neurol. 38(5), 705-713 (1995).
3. Askanas V, Engel WK. New advances in the understanding of sporadic inclusion-body myositis and hereditary inclusion-body myopathies. Curr. Opin. Rheumatol. 7(6), 486-496 (1995).
4. Argov Z, Yarom R. "Rimmed vacuole myopathy" sparing the quadriceps. A unique disorder in Iranian Jews. J. Neurol. Sci. 64(1), 33-43 (1984).
5. Argov Z, Mitrani-Rosenbaum S. The hereditary inclusion body myopathy enigma and its future therapy. Neurotherapeutics 5(4), 633-637 (2008).
6. Huizing M, Krasnewich DM. Hereditary inclusion body myopathy: a decade of progress. Biochim. Biophys. Acta 1792(9), 881-887 (2009).
7. Scriver's Online Metabolic and Molecular Bases of Inherited Disease. http://ommbid.mh me dical.com/book.aspx+bookID +474
8. Eisenberg I, Avidan N, Potikha T et al. The UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase gene is mutated in recessive hereditary inclusion body myopathy. Nat. Genet. 29(1), 83-87 (2001).
9. Hinderlich S, Stasche R, Zeitler R, Reutter W. A bifunctional enzyme catalyzes the frst two steps in N-acetylneuraminic acid biosynthesis of rat liver. Purifcation and characterization of UDP-N-acetylglucosamine 2-epimerase/N-acetylmannosamine kinase. J. Biol. Chem. 272(39), 24313-24318 (1997).
10. Varki A. Diversity in the sialic acids. Glycobiology 2(1), 25-40 (1992).
11. Keppler OT, Hinderlich S, Langner J, Schwartz-Albiez R, Reutter W, Pawlita M. UDP-GlcNAc 2-epimerase: a regulator of cell surface sialylation. Science 284(5418), 1372-1376 (1999).
12. Varki A. Sialic acids in human health and disease. Trends Mol. Med. 14(8), 351-360 (2008).
13. Noguchi S, Keira Y, Murayama K et al. Reduction of UDP-N- acetylglucosamine 2-epimerase/N-acetylmannosamine kinase activity and sialylation in distal myopathy with rimmed vacuoles. J. Biol. Chem. 279(12), 11402-11407 (2004).
14. Sparks SE, Ciccone C, Lalor M et al. Use of a cell-free system to determine UDP-N-acetylglucosamine 2-epimerase and N-acetylmannosamine kinase activities in human hereditary inclusion body myopathy. Glycobiology 15(11), 1102-1110 (2005).
15. Schwarzkopf M, Knobeloch KP, Rohde E et al. Sialylation is essential for early development in mice. Proc. Natl Acad. Sci. USA 99(8), 5267-5270 (2002).
16. Tajima Y, Uyama E, Go S et al. Distal myopathy with rimmed vacuoles: impaired O-glycan formation in muscular glycoproteins. Am. J. Pathol. 166(4), 1121-1130 (2005).
17. Huizing M, Rakocevic G, Sparks SE et al. Hypoglycosylation of alpha-dystroglycan in patients with hereditary IBM due to GNE mutations. Mol. Genet. Metab. 81(3), 196-202 (2004).
18. Broccolini A, Gidaro T, De Cristofaro R et al. Hyposialylation of neprilysin possibly affects its expression and enzymatic activity in hereditary inclusion-body myopathy muscle. J. Neurochem. 105(3), 971-981 (2008).
19. Ricci E, Broccolini A, Gidaro T et al. NCAM is hyposialylated in hereditary inclusion body myopathy due to GNE mutations. Neurology 66(5), 755-758 (2006).
20. Paccalet T, Coulombe Z, Tremblay JP. Ganglioside GM3 levels are altered in a mouse model of HIBM: GM3 as a cellular marker of the disease. PLoS ONE 5(4), e10055 (2010).
21. Galeano B, Klootwijk R, Manoli I et al. Mutation in the key enzyme of sialic acid biosynthesis causes severe glomerular proteinuria and is rescued by N-acetylmannosamine. J. Clin. Invest. 117(6), 1585-1594 (2007).
22. Malicdan MC, Noguchi S, Hayashi YK, Nonaka I, Nishino I. Prophylactic treatment with sialic acid metabolites precludes the development of the myopathic phenotype in the DMRV-hIBM mouse model. Nat. Med. 15(6), 690-695 (2009).
23. Sparks S, Rakocevic G, Joe G et al. Intravenous immune globulin in hereditary inclusion body myopathy: a pilot study. BMC Neurol. 7, 3 (2007).
24. Nemunaitis G, Maples PB, Jay C et al. Hereditary inclusion body myopathy: single patient response to GNE gene Lipoplex therapy. J. Gene Med. 12(5), 403-412 (2010).
25. Nemunaitis G, Jay CM, Maples PB et al. Hereditary inclusion body myopathy: single patient response to intravenous dosing of GNE gene lipoplex. Hum. Gene Ther. 22(11), 1331-1341 (2011).
26. Broccolini A, Gidaro T, Tasca G et al. Analysis of NCAM helps identify unusual phenotypes of hereditary inclusion-body myopathy. Neurology 75(3), 265-272 (2010).
27. Broccolini A, Gidaro T, Morosetti R et al. Neprilysin participates in skeletal muscle regeneration and is accumulated in abnormal muscle fbres of inclusion body myositis. J. Neurochem. 96(3), 777-789 (2006).
28. Valles-Ayoub Y, Esfandiarifard S, Sinai P et al. Serum neural cell adhesion molecule is hyposialylated in hereditary inclusion body myopathy. Genet. Test. Mol. Biomarkers 16(5), 313-317 (2012).
29. Savelkoul PJ, Manoli I, Sparks SE et al. Normal sialylation of serum N-linked and O-GalNAc-linked glycans in hereditary inclusion-body myopathy. Mol. Genet. Metab. 88(4), 389-390 (2006).
30. Wopereis S, Grunewald S, Huijben KM et al. Transferrin and apolipoprotein C-III isofocusing are complementary in the diagnosis of N-and O-glycan biosynthesis defects. Clin. Chem. 53(2), 180-187 (2007).
31. Liu Y, Xia B, Gleason TJ et al. N-and O-linked glycosylation of total plasma glycoproteins in galactosemia. Mol. Genet. Metab. 106(4), 442-454 (2012).
32. Carlson DM. Structures and immunochemical properties of oligosaccharides isolated from pig submaxillary mucins. J. Biol. Chem. 243(3), 616-626 (1968).
33. Faid V, Chirat F, Seta N, Foulquier F, Morelle W. A rapid mass spectrometric strategy for the characterization of Nand O-glycan chains in the diagnosis of defects in glycan biosynthesis. Proteomics 7(11), 1800-1813 (2007).
34. Xia B, Zhang W, Li X et al. Serum N-glycan and O-glycan analysis by mass spectrometry for diagnosis of congenital disorders of glycosylation. Anal. Biochem. 442(2), 178-185 (2013).
35. Guillard M, Morava E, Van Delft FL et al. Plasma N-glycan profling by mass spectrometry for congenital disorders of glycosylation type II. Clin. Chem. 57(4), 593-602 (2011).
36. Yoo E, Yoon I. Application of tandem mass spectrometry in the structure determination of permethylated sialic acid-containing oligosaccharides. Bull. Korean Chem. Soc. 26(9), 1347-1353 (2005).
37. Cunningham BA, Hemperly JJ, Murray BA, Prediger EA, Brackenbury. Neural cell adhesion molecule: structure, immunoglobulin-like domains, cell surface modulation, and alternative RNA splicing. Science 236(4803), 799-806 (1987).
38. Small SJ, Shull GE, Santoni MJ, Akeson R. Identifcation of a cDNA clone that contains the complete coding sequence for a 140-kD rat NCAM polypeptide. J. Cell. Biol. 105(5), 2335-2345 (1987).
39. Sharon N. Lectins: carbohydrate-specifc reagents and biological recognition molecules. J. Biol. Chem. 282(5), 2753-2764 (2007).
40. Iskratsch T, Braun A, Paschinger K, Wilson IB. Specifcity analysis of lectins and antibodies using remodeled glycoproteins. Anal. Biochem. 386(2), 133-146 (2009).
41. Kronis KA, Carver JP. Specifcity of isolectins of wheat germ agglutinin for sialyloligosaccharides: a 360-MHz proton nuclear magnetic resonance binding study. Biochemistry 21(13), 3050-3057 (1982).
42. Shibuya N, Goldstein IJ, Broekaert WF, Nsimba-Lubaki M, Peeters B, Peumans WJ. The elderberry (Sambucus nigra L.) bark lectin recognizes the Neu5Ac(alpha 2-6)Gal/GalNAc sequence. J. Biol. Chem. 262(4), 1596-1601 (1987).
43. Puri KD, Gopalakrishnan B, Surolia A. Carbohydrate binding specifcity of the Tn-antigen binding lectin from Vicia villosa seeds (VVLB4). FEBS Lett 312(2-3), 208-212 (1992).
44. Niethamer TK, Yardeni T, Leoyklang P et al. Oral monosaccharide therapies to reverse renal and muscle hyposialylation in a mouse model of GNE myopathy. Mol. Genet. Metab. 107(4), 748-755 (2012).
45. Harduin-Lepers A, Vallejo-Ruiz V, Krzewinski-Recchi MA, Samyn-Petit B, Julien S, Delannoy P. The human sialyltransferase family. Biochimie 83(8), 727-737 (2001).
46. Giacopuzzi E, Bresciani R, Schauer R, Monti E, Borsani G. New insights on the sialidase protein family revealed by a phylogenetic analysis in metazoa. PLoS ONE 7(8), e44193 (2012).
47. Pshezhetsky AV, Ashmarina LI. Desialylation of surface receptors as a new dimension in cell signaling. Biochemistry (Mosc.) 78(7), 736-745 (2013).
48. Springer GF. Immunoreactive T and Tn epitopes in cancer diagnosis, prognosis, and immunotherapy. J. Mol. Med. (Berl.) 75(8), 594-602 (1997).
49. Cao Y, Karsten UR, Liebrich W, Haensch W, Springer GF, Schlag PM. Expression of Thomsen-Friedenreich-related antigens in primary and metastatic colorectal carcinomas. A re-evaluation. Cancer 76(10), 1700-1708 (1995).
50. Goletz S, Cao Y, Danielczyk A, Ravn P, Schoeber U, Karsten U. Thomsen-Friedenreich antigen: the "hidden" tumor antigen. Adv. Exp. Med. Biol. 535, 147-162 (2003).
51. Imai J, Ghazizadeh M, Naito Z, Asano G. Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma. Anticancer Res. 21(2B), 1327-1334 (2001).
52. Udd B. Distal myopathies-new genetic entities expand diagnostic challenge. Neuromusc. Disord. 22(1), 5-12 (2012).
53. Muntoni F, Torelli S, Wells DJ, Brown SC. Muscular dystrophies due to glycosylation defects: diagnosis and therapeutic strategies. Curr. Opin. Neurol. 24(5), 437-442 (2011).
54. Abes R, Teillaud J-L. Impact of glycosylation on effector functions of therapeutic IgG. Pharmaceuticals 3, 146-157 (2010).